Tennessee CBD-Oil Affirmative Defense

Last verified: May 2026

The 2014 Origin and the 2021 Expansion

Tennessee technically referenced "medical cannabis" research as far back as the 1981 Cannabis Control Act, but the modern functional carve-out dates to 2014 (SB 2531), modified in 2015 (SB 280), 2016, and 2021 (SB 118). The 2021 expansion — signed by Gov. Lee on May 27, 2021 alongside the bill creating the TMCC — raised the allowable THC ceiling from 0.6% to 0.9% and expanded the qualifying-condition list to nine.

Statutory Mechanics — What § 39-17-402(16)(F) Actually Does

T.C.A. § 39-17-402(16) defines "marijuana" for purposes of the controlled-substances scheduling under § 39-17-415. Subsection (F) excludes CBD oils containing less than 0.9% delta-9 THC from that definition only when paired with the patient’s qualifying documentation. T.C.A. § 63-1-127 governs Tennessee-licensed physician participation. The exemption is an affirmative defense at trial, not a true legalization — meaning the patient must prove eligibility after being charged with possession.

What Is Allowed

A person may possess CBD oil with less than 0.9% THC if:

1. The bottle is labeled by the manufacturer as containing CBD with less than 0.9% THC, with manufacturer’s name, expiration date, batch/lot number, and THC concentration; and
2. The person possesses (a) a written legal order or recommendation from another state where such oil is legal, and (b) proof that the person or an immediate family member has been diagnosed with one of the qualifying conditions (see qualifying conditions page) by a Tennessee-licensed M.D. or D.O.

Physician letters are valid for six months and must be renewed.

The Fatal Flaw — No In-State Production or Sale

Crucially, no person, business, or institution in Tennessee is authorized to produce, dispense, or sell the qualifying CBD oil. Patients must travel to a state with a reciprocity-friendly medical program (typically Mississippi, Arkansas, Missouri, Virginia, or Kentucky once dispensary supply matures) and bring product back. Federal interstate-commerce prohibitions on Schedule III substances (cannabis with THC over 0.3% became federal Schedule III in December 2025, but transport across state lines remains tightly restricted) make this legally fraught.

A 2018 raid of Tennessee retailers selling unauthorized CBD products by the Tennessee Bureau of Investigation ultimately resulted in dropped charges — but the episode reinforced that the carve-out provides a defense, not an access pathway.

Affirmative Defense vs. Legalization — Why the Distinction Matters

An affirmative defense is a defense raised at trial after the prosecution proves the elements of the offense. The patient must:

• Be arrested and charged with possession of marijuana under § 39-17-418 or PWID under § 39-17-417.
• Hire defense counsel and prepare for trial (or plea negotiations).
• Produce, at trial, the manufacturer label, the qualifying physician’s diagnosis letter, and the out-of-state legal order or recommendation.
• Persuade the trial court that all statutory elements of the defense are satisfied.

The collateral consequences of even a successfully defended arrest — bond, attorney fees, missed work, employment screening, immigration consequences for non-citizens — remain. The CBD-oil pathway protects against conviction; it does not protect against arrest, prosecution, or the entire weight of the criminal-justice process.

Practical Utility — Who This Actually Helps

For the small number of patients actually able to navigate this — primarily families of children with intractable epilepsy and certain ALS and end-stage cancer patients — the carve-out provides protection from prosecution. For everyone else, including the vast majority of patients who could benefit from medical cannabis (chronic pain, PTSD, anxiety, and most cancer patients not in end-stage), the law is functionally inaccessible.

The reach is intentionally narrow. The Tennessee Medical Association has historically endorsed CBD-oil expansion but has not endorsed comprehensive medical cannabis. Sen. Janice Bowling (R-Tullahoma), one of the original 2014 sponsors, has spent more than a decade trying to expand the framework into a true medical program; that effort has yet to clear the Republican supermajority.

What This Defense Does NOT Cover

• Flower: smokable cannabis flower, even if low-THC, is not within the § 39-17-402(16)(F) carve-out.
• Edibles, tinctures, vape carts, topicals, beverages: only "oil" is covered, and only at < 0.9% THC.
• Possession without the documentation set: the patient must have all three documents (label, out-of-state legal order, in-state physician diagnosis).
• DUI: the affirmative defense to possession does not eliminate DUI exposure under § 55-10-401. Impairment is a separate question. See DUI page.
• Workplace drug-screen consequences: at-will employment plus the Drug-Free Workplace Programs Act (T.C.A. § 50-9-101 et seq.) means a positive screen, even from legal CBD oil, can support termination. See workplace page.

The Bigger Picture

The CBD-oil defense and the TMCC are the two narrow medical-cannabis instruments Tennessee has; both are intentionally limited. The CBD-oil defense protects a tiny patient population from conviction; the TMCC studies a future framework that legislative leadership has refused to enact. Functionally, Tennessee remains one of the most restrictive medical-cannabis states in the country — comparable only to Idaho, Wyoming, Kansas, South Carolina, and (now) Indiana in offering essentially no functional medical-cannabis access. See TMCC page.